Natural killer, or NK, cell testing is one of the more expensive and more debated add-on tests offered at some fertility clinics, particularly for patients dealing with recurrent implantation failure or recurrent pregnancy loss. It's also a good case study in the gap between a biologically plausible theory and clinically proven, actionable evidence. Here's what the research actually shows.
The biological theory behind NK cell testing
NK cells are part of the innate immune system and play a real, well-established role in maintaining maternal-fetal immune tolerance and regulating how the placenta invades the uterine lining during early pregnancy. The theory behind testing is straightforward: if a patient's NK cell levels or activity are abnormally elevated, perhaps that immune activity is attacking the embryo and preventing implantation or causing early loss, and treating it with immunosuppressive therapy could improve outcomes.
What the evidence actually shows
The American Society for Reproductive Medicine's guideline on immunotherapy in IVF found that immunotherapies reviewed, including NK cell-directed treatments, are either not associated with improved live birth outcomes or have been insufficiently studied to make definitive recommendations. The guideline specifically flagged that stability and meaning of NK cytotoxicity assays are poorly defined and not in routine clinical use even among the immunology and rheumatology community, and that most supportive studies were retrospective, small, and not conducted with modern standards for controlled trial design.
A systematic review and meta-analysis specifically evaluating NK cells in female infertility and recurrent miscarriage found no significant difference in live birth rates between women with elevated peripheral NK cells or NK activity and those without. The same review found conflicting results depending on whether NK cells were measured as raw numbers versus percentages, an inconsistency that itself points to real measurement and methodology problems with the test. Its authors concluded that on the basis of current evidence, NK cell analysis and immune therapy should be offered only in the context of clinical research, not as routine clinical care.
Why some clinics still offer it
NK cell testing and associated immune treatments, such as intralipids, IVIG, or steroids, remain available at some clinics, often marketed toward patients who've experienced the genuine heartbreak of recurrent implantation failure or recurrent loss and are looking for any additional avenue to explore. That emotional context is real and understandable. It doesn't change what the current evidence shows, but it's worth naming honestly rather than dismissing why the demand for this testing persists.
What some of these treatments involve, and their own evidence gaps
- Intralipid infusions, an intravenous fat emulsion theorized to modulate NK cell activity, lacks robust randomized controlled trial support for improving live birth rates.
- IVIG (intravenous immunoglobulin), an expensive infusion therapy, has similarly limited high-quality evidence in this specific context and carries its own side effect profile.
- Corticosteroids, sometimes prescribed around transfer time based on immune theory, also lack strong RCT support for this specific indication, and long-term or repeated steroid use carries its own risks worth weighing.
What specific test is being used, and what's the evidence base behind it, is it a peer-reviewed, validated assay, or a proprietary or less-standardized test? Is this treatment being offered inside a formal clinical trial or research protocol, where you'd have appropriate informed consent about its investigational status? What's the total added cost, and how does that compare to spending the same money on additional cycles or PGT-A testing, where the evidence base is considerably stronger?
The honest bottom line
NK cells are biologically real and play a genuine role in pregnancy. But the leap from that biological fact to "testing your NK cells and treating abnormal results will improve your live birth odds" isn't supported by the strongest current evidence, according to ASRM's own guidance and independent systematic reviews. That doesn't mean the theory is permanently closed, ASRM's language leaves room for future, better-designed research to change this picture. It does mean that, as of now, this remains investigational rather than standard of care.
Frequently asked questions
Should I refuse NK cell testing if my clinic offers it?
That's a personal decision. Some patients feel the emotional value of exploring every option outweighs the weak evidence base; others prefer to direct that money and effort toward interventions with stronger data. Neither choice is wrong, but making it with a clear understanding of the actual evidence, rather than marketing language, is worth insisting on.
Is this different from standard immune workups for recurrent pregnancy loss?
Yes, somewhat. Standard recurrent pregnancy loss workups typically include tests with more established clinical utility, like antiphospholipid antibody syndrome screening and thyroid function. NK cell testing specifically is the more contested, less validated piece of a broader immune evaluation.
Has any research supported NK cell treatment for specific subgroups?
Some smaller, mostly retrospective studies have suggested benefit in specific patient subgroups, but the ASRM guideline and subsequent meta-analyses haven't found this rises to the level of changing practice recommendations. If you fall into a subgroup a specialist believes might benefit, ask specifically what study that recommendation is based on.